Kazia Therapeutics Deuda/Patrimonio neto
¿Qué es el Deuda/Patrimonio neto de Kazia Therapeutics?
El Deuda/Patrimonio neto de Kazia Therapeutics Limited es 1.33
¿Cuál es la definición de Deuda/Patrimonio neto?
La relación deuda / patrimonio neto es una relación financiera que indica la proporción relativa del capital contable y la deuda utilizada para financiar los activos de una empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Deuda/Patrimonio neto de compañías en Sector Health Care en ASX en comparadas con Kazia Therapeutics
¿Qué hace Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas con deuda/patrimonio neto similar a Kazia Therapeutics
- Ambertech tiene Deuda/Patrimonio neto de 1.33
- ORBIS AG tiene Deuda/Patrimonio neto de 1.33
- Viatris tiene Deuda/Patrimonio neto de 1.33
- L1 Long Short Fund Ltd tiene Deuda/Patrimonio neto de 1.33
- Nexus Real Estate Investment Trust tiene Deuda/Patrimonio neto de 1.33
- Sahyog Multibase tiene Deuda/Patrimonio neto de 1.33
- Kazia Therapeutics tiene Deuda/Patrimonio neto de 1.33
- Truscott Mining tiene Deuda/Patrimonio neto de 1.33
- Diversified Healthcare Trust tiene Deuda/Patrimonio neto de 1.33
- WWPKG tiene Deuda/Patrimonio neto de 1.33
- Alimentation Couche-Tard tiene Deuda/Patrimonio neto de 1.33
- Alimentation Couche-Tard tiene Deuda/Patrimonio neto de 1.33
- InvesTech tiene Deuda/Patrimonio neto de 1.33